Pharmafile Logo

Confidential contracting

- PMLiVE

Insights From ISPOR 2025: R In Health Technology Assessment – Is It The Future?

ISPOR’s annual meeting in Montreal this May was packed with opportunities to explore the latest trends, insights, and research in HEOR and market access. In this series, our experts share...

Petauri Evidence

- PMLiVE

30 Years of Innovation in Education at HLTH Europe

The Medscape Education Global team will be travelling to Amsterdam for the HLTH Europe 2025 conference to showcase the power and value of CME. As pioneers in clinician education for...

Medscape Education

- PMLiVE

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

- PMLiVE

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Pfizer shares ‘unprecedented’ survival results for Braftovi in colorectal cancer

Around 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

- PMLiVE

Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links